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Abstract
Background: Smear-negative pulmonary tuberculosis (SNPTB) accounts for 30% of Pulmonary
Tuberculosis (PTB) cases reported annually in developing nations. Polymerase chain reaction (PCR)
may provide an alternative for the rapid detection of Mycobacterium tuberculosis (MTB); however
little data are available regarding the clinical utility of PCR in SNPTB, in a setting with a high burden
of TB/HIV co-infection.
Methods: To evaluate the performance of the PCR dot-blot in parallel with pretest probability
(Clinical Suspicion) in patients suspected of having SNPTB, a prospective study of 213 individuals
with clinical and radiological suspicion of SNPTB was carried out from May 2003 to May 2004, in a
TB/HIV reference hospital. Respiratory specialists estimated the pretest probability of active
disease into high, intermediate, low categories. Expectorated sputum was examined by direct
microscopy (Ziehl-Neelsen staining), culture (Lowenstein Jensen) and PCR dot-blot. Gold standard
was based on culture positivity combined with the clinical definition of PTB.
Results: In smear-negative and HIV subjects, active PTB was diagnosed in 28.4% (43/151) and
42.2% (19/45), respectively. In the high, intermediate and low pretest probability categories active
PTB was diagnosed in 67.4% (31/46), 24% (6/25), 7.5% (6/80), respectively. PCR had sensitivity of
65% (CI 95%: 50%–78%) and specificity of 83% (CI 95%: 75%–89%). There was no difference in the
sensitivity of PCR in relation to HIV status. PCR sensitivity and specificity among non-previously
TB treated and those treated in the past were, respectively: 69%, 43%, 85% and 80%. The high
pretest probability, when used as a diagnostic test, had sensitivity of 72% (CI 95%:57%–84%) and
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specificity of 86% (CI 95%:78%–92%). Using the PCR dot-blot in parallel with high pretest
probability as a diagnostic test, sensitivity, specificity, positive and negative predictive values were:
90%, 71%, 75%, and 88%, respectively. Among non-previously TB treated and HIV subjects, this
approach had sensitivity, specificity, positive and negative predictive values of 91%, 79%, 81%, 90%,
and 90%, 65%, 72%, 88%, respectively.
Conclusion: PCR dot-blot associated with a high clinical suspicion may provide an important
contribution to the diagnosis of SNPTB mainly in patients that have not been previously treated
attended at a TB/HIV reference hospital.
Background
Tuberculosis (TB) is one of the most widespread mortal-
ity-causing infectious diseases in humans. Timely detec-
tion of the disease allows the institution of an effective
and life-saving treatment, thereby reducing transmission
to close contacts. Conventional diagnosis of Pulmonary
Tuberculosis (PTB) is time-consuming, and the acid fast
bacilli (AFB) smear has a low sensitivity (40%–60%) [1].
HIV infection has been associated with an increased inci-
dence of smear negative pulmonary tuberculosis (SNPTB)
and a higher mortality rate in TB patients. [2-4]. In Brazil,
almost 30% of PTB cases among adults are SNPTB [2-4].
Diagnosis of SNPTB is a difficult task and, in developing
countries, the majority of these cases have been treated
only on the basis of clinical and chest radiographic find-
ings. Without a standardized clinical work up, the misdi-
agnosis rates have been estimated to be as high as 35%
[5]. Therefore, in settings with a high rate of TB and HIV,
the clinical evaluation of new tools for smear negative PTB
diagnoses is extremely valuable [1,6]
In industrialized countries, tests for Mycobacterium tuber-
culosis (MTB), using rapid nucleic acid amplification
(NAA), have been considered a major breakthrough in the
diagnosis of PTB [7]. In developing countries, the in house
polymerase chain reaction (PCR) for amplification of
MTB DNA, using the IS6110 insertion element as a target,
offers a potentially sensitive, specific and low-cost test that
could provide a rapid diagnosis of PTB [8-11].
In these settings, the published evaluations of NAA tech-
niques for smear negative PTB diagnosis have been based
mainly on laboratory criteria for diagnosis of disease with
or without clinical records used to evaluate discrepant
results [11-17].
In the present study, we investigated the performance of a
home-made colorimetric PCR (PCR dot-blot) to diagnose
TB using expectorated sputum from patients suspected of
having SNPTB, in isolation and in parallel with pretest
probability (based on Clinical Suspicion) in a hospital
setting with a high burden of TB and HIV. The PCR tech-
nique performance was compared with conventional rou-
tine diagnostic methods for smear negative patients.
Methods
Setting and patient selection
Consecutive adults suspected of having SNPTB, referred to
the TB and HIV Reference Center, Parthenon Reference
Hospital (PRH) in Porto Alegre City, capital of Rio Grande
do Sul, State of Brazil, were studied prospectively, from
May 2003 to May 2004. SNPTB suspects were referred
from community health care units to have their respira-
tory specimens cultured for mycobacteria, according to
Brazilian National Guidelines [18].
Eligible patients were those: (1) who reported more than
3 weeks of cough; (2) who had two consecutive samples
of spontaneous sputum that were acid fast bacilli smear-
negative. Patients illegible were those receiving anti-TB
treatment. Patients with a history of previous TB were not
excluded. Patients were excluded from the study if any of
the following conditions were met: (1) culture was con-
taminated; (2) when expectorated sputum was not
obtained (3) laboratory or clinical data did not fulfill the
SNPTB definition; (4) written informed consent was not
obtained from the study participant. All clinical samples
were sent to the Laboratory of the State of RS, State Foun-
dation for Research in Health, Porto Alegre/RS/Brazil,
(FEEPS/Lacen/RS) for laboratory analysis. This study was
approved by the Institutional Review Boards of FEPPS/RS
(n. 01/2002).
Suspects of SNPTB, after signing their written informed
consent, underwent a validated questionnaire with ques-
tions regarding demographic variables and clinical history
(e.g.: smoking, alcohol abuse, HIV infection/AIDS)[19].
Chest radiographs and physical examination was per-
formed by a respiratory specialist using a standardized
form. Respiratory specialists were blinded for the results
of cultures and PCR dot-blot, and laboratory technicians
were blinded for the chest radiographs results and clinical
predictors. HIV testing by ELISA was performed, using
Western blot as a confirmatory test.
Estimate of pretest probability
To estimate pretest probability (clinical suspicion), all eli-
gible individuals were classified into three relative risk cat-
egories during the first appointment: low (≤ 25%);
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intermediate (26%–75%); and high (>75%) pretest prob-
abilities of active PTB. Classifications were made by four
respiratory specialists (2 with 10 years of experience and 2
with 20 years of experience in diagnosing TB). This was an
estimate of disease probability based on clinical history,
physical examination, other laboratory data available
besides microbiological tests, and chest radiographs eval-
uation performed using a validated form [19].
Radiographic analysis
Chest radiographs were classified as typical, compatible,
atypical and normal. Typical were those considered as
having any parenchymal infiltrate or cavity localized in
the upper zone (defined as the area above the posterior
third rib); compatible were those presenting a miliary pat-
tern, pleural effusion or thoracic adenopathy, and atypical
those showing any other abnormality [19].
Case definition
PTB cases were defined as those with a positive culture for
MTB in the respiratory specimen or those with clinical and
radiological improvement after six months of solely anti-
TB treatment, as judged by three different chest physicians
in a blinded review, not involved in this study [20]. Non-
PTB was considered in patients whose acid-fast smear and
culture for MTB were negative and who had no chest radi-
ographic changes after six months of follow-up. PCR
results were not available for routine care or for the panel
of experts.
Gold standard criteria for SNPTB final diagnosis included
all PTB cases, confirmed or not by culture.
Routine laboratory process
All sputum specimens were processed at the Public Refer-
ence Laboratory. All sputum specimens were tested by the
Ziehl- Neelsen method, cultured in Lowentein Jensen and
identified according to Kubica's method [21].
The presence of the amplified fragment derived from
IS6110 insertion element sequence in PCRs positives was
checked by electrophoresis with 2% agarose gel, stained
with ethidium bromide, and visualized under ultraviolet
light [16]. The positive and negative controls were
included in electrophoresis analysis.
The PCR colorimetric dot-blot assay was performed as
previously published [16]. Briefly, the biotinylated PCR
products were transferred to a nylon membrane and
hybridization was performed with a specific probe. The
detection of hybridization was performed using a conju-
gated streptavidin-alkaline phosphatase probe. The posi-
tive reaction was obtained by adding BCIP and NBT (5-
bromo-4-chloro-3-indoyl phosphate and nitro blue tetra-
zolium). The positive and negative controls were included
for each set of PCR. To detect specimen inhibitors in neg-
ative results, a tube of PCR mix for each specimen was
spiked with purified DNA target. All PCRs tests with dis-
crepancies in results were tested in duplicate.
Data analysis
Epidemiological and laboratory data were entered into a
computer database and analyzed by appropriate statistical
software (SPSS version 10.0). The endpoints were sensitiv-
ity (SE), specificity (SP), positive and and positive and
negative predictive values (PPV, NPV) for detection in
smear-negative subjects. For MTB DNA detection, the
analyses of PCR SE, SP, PPV, NPV were performed on a
per-study-subject basis, using the diagnosis of PTB as a ref-
erence standard (defined above). Agreement between the
PCRs duplicates was evaluated using the Kappa score, a
measurement of agreement that considers the excess of
the amount of agreement that could be expected by
chance.
For secondary analysis, using the high pretest probability
(HPP) as a diagnostic test, suspects of SNPTB with high
pretest probabilities were considered as positive for active
PTB, and those with intermediate and low pretest proba-
bilities were considered negative.
Additionally, test performances of HPP in parallel with
PCR as a diagnostic test were calculated using specific for-
mulas: SE of HPP with PCR: SEHPP + SEPCR- (SEHPP + SEPCR),
predictive values (PV) for different prevalence rates
according to the literature [22].
Results
Of the total of 277 SNPTB suspects enrolled, 64 (23.1%)
were not included in the analysis for the following rea-
sons: 63 (22.6%) had an incomplete set of clinical data
(14 patients had no chest X-ray available; 48 did not fulfill
the SNPTB definition, one refused to participate, and the
culture of one was contaminated. Of the 213 SNPTB sus-
pects included in the analysis, all with known HIV test
results, 104 (48.8%) were diagnosed with active TB. Strat-
ifying by HIV status, the sensitivity of acid-fast bacilli in
expectorated sputum was lower in HIV seropositive than
in HIV seronegative suspects of SNPTB (67% vs 41%; p =
0.01). Among the 213 SNPTB suspects, 62 (29%) had pos-
itive smear acid-fast bacilli tests and were excluded. In this
study, data were analyzed for 151 SNPTB suspects with
negative smear tests. Overall, active PTB was diagnosed in
28.4% (43/151) of patients, HIV infection in 29.8% (45/
151), and a history of previous PTB was referred to by
35.0% (53/151). Positive culture results occurred in
69.8% (30/43) of all TB cases, and 73.7% (14/19) of HIV
seropositive TB cases.
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Analysis of pretest probability (clinical suspicion) for PTB
Clinical features of SNPTB suspects are shown in Table 1.
In 151 SNPTB suspects, according to risk categories, the
prevalence of PTB in high, intermediate and low clinical
pretest probabilities was 67.4% (31/46), 24% (6/25) and
7.5% (6/80), respectively (p < 0.05). The proportion of
patients with a suggestive chest radiograph increased
steadily in those with a clinical suspicion of TB groups;
0% of low probability patients had suggestive radio-
graphs, 24% in the intermediate group, and 78% of the
high level group (p < 0.001).
Comparative performance analysis of tests
The performance of tests for detection of MTB and diagno-
sis of PTB are shown in Table 2. The PCR sensitivity was
65% (CI 95%, 50%–78%) and specificity was 83% (CI
95%, 75%–89%).
When the pretest probability (Clinical Suspicion) is used
as a diagnostic test, the high pretest probability sensitivity
was 72% and specificity was 86%. The Intermediary pre-
test probability sensitivity was 14% and specificity was
82%. The Low pretest probability sensitivity was 14% and
specificity was 31%.
PCR had a similar sensitivity to the culture results (65% vs
70%, p = 0.65) and to the high pretest probability (65%
vs 72%; p = 0.66). The PCR dot-blot demonstrated 18
false-positive results (9 had TB in the past, 1 presented a
scar image in the chest X-ray that resembled inactive TB, 4
were HIV+, 4 referred proximity with smear positive PTB
cases in the last 6 months). The PCR dot-blot demon-
strated 15 false-negative results. The value of the Kappa
score obtained between the duplicates of PCRs was 100%.
PCR dot-blot inhibition was found in one SNPTB suspect
(2.3%).
In a parallel evaluation, the sensitivity of PCR used in par-
allel with the high pretest probability was higher than the
sensitivity of the high pretest probability when used alone
(90% vs 72%), and of culture sensitivity (90% vs 70%)
(Table 2B). PCR colorimetric dot-blot assay, used in par-
allel with the high pretest probability, had a PPV and NPV
of 75% and 88%, respectively. The NPV was similar to
that observed with culture alone (88% vs 89%). Compar-
ing the SE and NPV of PCR used in parallel with the high
pretest probability among those individuals not previ-
ously treated and those treated for TB in the past, the fig-
ures were respectively 91%, 90% vs 83%, 79%, p > 0.05.
In HIV seropositive subjects, the sensitivity of PCR was
63% (CI 95%, 40%–82%), and specificity was 85% (CI
95%, 66%–94%). The PCR sensitivity was similar to that
of culture (74%) and to the high pretest probability
method (74%). The PCR colorimetric dot-blot assay, used
in parallel with the high pretest probability, had a SE, SP,
PPV and NPV of 90%, 65%, 72%, and 88%, respectively.
In HIV seronegative subjects the sensitivity of PCR was
66%, and specificity was 83%. PCR sensitivity was similar
to that of culture (67%) and to the high Pretest Probabil-
ity method (71%). The PCR colorimetric dot-blot assay
used in parallel with the high pretest probability had a SE,
SP, PPV and NPV of 90%, 74%, 77%, and 89%, respec-
tively.
Considering the HIV status and comparing the SE and
NPV of PCR with high pretest probability among those
individuals not previously treated and those treated for TB
in the past, the figures were respectively: 91%, 90%, and
89%, 88% for HIV seropositive subjects and 93%, 92%
and 83%, 80% for HIV seronegative group.
Table 1: Patient symptoms and medical history, associated with physicians' clinical suspicion of tuberculosis among smear-negative 
PTB suspects
Clinical Suspicion of Tuberculosis Group Smear-Negative PTB suspects
Symptoms and Medical History N = 151 (%) Low (N = 80) Intermediate (N = 25) High (N = 46)
Suggestive chest radiographya 42 (27.8%) 0 6 36
Weight loss 81 (53.6%) 37 12 32
Cough 135 (89.4%) 73 23 39
Chest pain 89 (58.9%) 48 15 26
Dyspnea 105 (69.5%) 57 17 31
Tuberculosis exposure at home 74 (49.0%) 37 14 23
Hospital admission in the last 24 months 53 (35.1%) 24 10 19
Hepatitis 31 (20.5%) 12 5 14
Immune suppression b 51 (33.8%) 17 13 21
a: intake chest radiograph was suggestive of classical tuberculosis (upper-lobe fibrocavitary) disease.
b: includes patients positive for the human immunodeficiency virus (27.2%) and those with a history of steroid use or cancer chemotherapy (3.6%)
BMC Public Health 2007, 7:356 http://www.biomedcentral.com/1471-2458/7/356
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Table 2: Performance of Culture, PCR dot-blot and Clinical suspicion tests, individually and associated, in 151 smear negative PTB 
suspects
Table 2A. Laboratory results and Performance of methods
All Groupa
N = 151
Non previously TB treated Groupb
N = 98
TB
N = 43
Non-TB
N = 108
TB
N = 36
Non-TB
N = 62
Culture Positive 30 0 27 0
Negative 13 108 9 62
SE SP PPV NPV SE SP PPV NPV
70% 100% 100 89 75% 100% 100 87
PCR dot-blot Positive 28 18 25 9
Negative 15 90 11 53
SE SP PPV NPV SE SP PPV NPV
65% 83% 61 86 69% 85% 73 83
High PP Positive 31 15 26 4
Negative 12 93 10 58
SE SP PPV NPV SE SP PPV NPV
72% 86% 67 88 72% 93% 87 85
Intermediate PP Positive 6 19 6 6
Negative 37 89 30 56
SE SP PPV NPV SE SP PPV NPV
14% 82% 24 71 17% 90% 50 65
Low PP Positive 6 74 4 52
Negative 37 34 32 10
SE SP PPV NPV SE SP PPV NPV
14% 31% 7.5 48 11% 16% 7.1 24
Table 2B. Performance of methods used in parallel
Performance of PCR dot-blot in parallel with High Clinical Suspicion SE SP PPV NPV SE SP PPV NPV
90% 71% 75 88 91% 79% 81 90
Performance of PCR dot-blot in parallel with Intermediate Clinical 
Suspicion
SE SP PPV NPV SE SP PPV NPV
70% 68% 68 70 74% 77% 75 76
Performance of PCR dot-blot in parallel with Low Clinical Suspicion SE SP PPV NPV SE SP PPV NPV
26% 25% 47 47 26% 14% 45 34
SE: Sensitivity, SP: Specificity, PPV: Positive Predictive Value, NPV: Negative Predictive Value, PP: pretest probability (clinical suspicion).
a: All group.
b: Non previously TB treated group patients
BMC Public Health 2007, 7:356 http://www.biomedcentral.com/1471-2458/7/356
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An increased sensitivity of PCR, when used in parallel
with the high pretest probability, was observed in non-
previously treated patients, compared to those who had
had previous anti-TB treatment (sensitivity: 91% vs 83%).
Similar results were found in HIV seropositive study sub-
jects, in which the sensitivity was 91% among non-previ-
ously treated cases and 89% among those treated in the
past. In HIV seronegative suspects, similar results were
observed, in which sensitivity was 93% among non-previ-
ously treated cases and 83% among those treated in the
past.
An increased specificity of PCR associated with a high pre-
test probability was observed in non-previously treated
patients, compared to those who had previous anti-TB
treatment (specificity: 79% vs 61%). Similar results were
found in HIV seropositive study subjects: specificity was
79% among non-previously treated cases and 75% among
those treated in the past. In HIV seronegative subjects,
using the same diagnostic test, the specificity was 80%
among non-previously treated cases and 62% among
those treated in the past.
Assuming different TB prevalence scenarios, the use of the
PCR colorimetric dot-blot in parallel with a high clinical
suspicion of SNPTB showed similar positive and negative
PVs, among HIV seropositive and HIV seronegative
patients (Figure 1). In regions from developing nations
with a estimated TB prevalence of 5%–10%, described in
out-patient units attending persons with coughs for more
than three weeks (respiratory symptomatic, according to
WHO), NPV for the PCR colorimetric dot-blot technique
Simulation of positive and negative predictive values of ZN and Culture/PCR dot-blot tests, according to different TB preva-lence ratesFig re 1
Simulation of positive and negative predictive values of ZN and Culture/PCR dot-blot tests, according to dif-
ferent TB prevalence rates. PPV: Positive Predictive Value, NPV: Negative Predictive Value, PP: pretest probability (clinical 
suspicion); TB prevalence rates: from 5% to 48.8%
BMC Public Health 2007, 7:356 http://www.biomedcentral.com/1471-2458/7/356
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used in parallel with a high clinical suspicion of SNPTB,
ranged from 98 to 99%, among HIV seropositive and HIV
seronegative subjects. In Health Units, in which the prev-
alence ranges from 15% to 20%, usually in General Hos-
pitals or Ambulatory Reference Centers (TB Clinics),
negative PV of this diagnostic strategy ranged from 96% to
97%. In Reference TB Hospitals where the TB prevalence
ranges from 30% to 40%, among HIV seronegative indi-
viduals, NPV of PCR colorimetric dot-blot, used in paral-
lel with a high clinical suspicion of SNPTB, ranged from
95% to 92%, and among HIV seropositive individuals,
this figure was of 94% and 91%, respectively (Figure 1).
The median time to reveal growth of MTB was 30 days
(interquartile range [IQR] 30 to 45) for culture and the
median time for detection of MTB by PCR was 3.32 days
(IQR 3.0 to 3.75), respectively (p < 0.01). Within one
week, of the 30 positive cultures, none were positive,
whilst PCR detected 93% of positive specimens (p < 0.01).
Discussion
We evaluated the performance of tests in SNPTB suspects.
The strengths of this study, carried out in a developing
country, included: a) a large number of SNPTB suspects,
b) comparison were made according to HIV status, history
of previous anti-TB treatment, the different levels of clini-
cal suspicion and pretest probability and, c) the prospec-
tive design, ensuring a more complete clinical, laboratory,
and radiographic information. Individuals were carefully
characterized by independent reviews to determine the
final diagnosis.
In this study, performed at the Hospital Reference Center,
we observed a high prevalence of active PTB (48.8%) and
TB/HIV co-infection (29.8%), confirming the epidemio-
logical data described by the TB Control Program of Porto
Alegre City, where 29% of all new TB cases reported yearly
are diagnosed in hospitals and where there is a high TB
and HIV burden [23].
The prevalence of PTB for the high pretest probability
group was 67.4%, lower than that described in the litera-
ture where smear-positive and smear-negative PTB were
included in analyses, the prevalence of PTB for intermedi-
ate pretest probabilities was 24%, similar to that (29%)
described by Catanzaro, but higher than that described by
Lim (3.4%). PTB prevalence for low pretest probability
was 7.5%, higher than that cited elsewhere with low bur-
dens of TB and HIV infection in health settings [24-26].
The moderate PCR sensitivity and specificity in SNPTB
suspects (sensitivity: 65%; specificity: 83%) observed
were similar to the sensitivities (61%–83%) and specifici-
ties (84%–92%) described by others [11,13,14]; however
the specificities obtained were lower than those described
in industrialized countries (>95%) [27]. As mentioned by
others, in this report, the sensitivity of PCR was not influ-
enced by the HIV status of the patient [12,28].
Decreased sensitivities of new diagnostic tests are expected
among smear-negative pulmonary TB cases. In this study,
this may be due to: 1) the presence of inhibitors that
remain in the specimen after the extraction procedure; 2)
a small number of mycobacteria unequally distributed in
the test suspension; 3) a mycobacterium level that is
below the detection limit of in house PCR (50 CFU) [16].
The proportion of inhibitors was 2.3%, and this result was
lower than that reported by other studies using home-
made PCR (22.7%) and similar to those using automated
NAA (0.85%–5.0%) [17,27,29]. Twenty-three specimens
presented less than 50 CFU in culture, which is below the
detection limit of the test. Partial loss of mycobacterial
homogeneity, leading to unequal distribution in the test
suspension, may be due to the division of the suspension
into three aliquots for use in laboratory tests. Addition-
ally, a potential source of decreased sensitivity may be the
use of the IS6110 insertion element as the target for PCR,
since MTB can present low copy numbers of the element.
Meanwhile, DNA fingerprinting studies, performed in
Brazil, did not find the presence of these strains, as men-
tioned by Sperhacke et al.[16].
The decrease in specificity was due to eighteen false-posi-
tive results from patients that referred to previous anti-TB
treatment, thus it is not surprising that DNA could be
detected in their respiratory specimens, however the
period elapsed between the end of previous anti-TB treat-
ment in these patients and the reported positive PCR anal-
yses was not collected, and this is a limitation of this
study.
Using a high pretest probability as a diagnostic test for
SNPTB diagnosis, this test had a sensitivity of 72% and a
specificity of 86%; these values were similar to those
observed with culture and PCR. These low accuracies can
be explained by the fact that the evaluation of patients was
performed by young or less experienced physicians, as
described by LIM et al.[30]. The large disparity in sensitiv-
ities found when the clinical suspicion (pretest probabil-
ity) is used as a diagnostic test, can be explained due to: a)
the classification in risk categories based on based on clin-
ical data, b) different years of experience in the SNPTB
diagnosis of physicians that evaluated the patients. There-
fore, when a high, intermediate and low probability pre-
test is used as a diagnostic test, patients with high risk had
sensitivities higher than those of patients with intermedi-
ate and low risk, because these patients had more symp-
toms compatible with SNPTB.
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The clinical evaluation used in parallel with the PCR test
may be an alternative to the use of the PCR test for rapid
diagnosis of PTB, especially in a hospital setting with a
high burden of TB/HIV co-infection. The combination of
clinical judgment and amplification results strongly
enhances a rapid and correct diagnosis of PTB [26].
In this study, when we used PCR in parallel with high pre-
test probability, the diagnostic appeared to offer a higher
negative predictive value in SNPTB subjects that had not
been previously treated and in HIV seronegative cases, as
described by others [24,25,30]. In non-previously treated
and HIV seronegative cases, the performance results (SE:
93%; NPV: 92%) were similar to those recently described
by Piersimoni et al, using automated tests in 214 PTB sus-
pects [26].
Due to the small number of active TB in the group with
the low pretest probability, additional evaluation is war-
ranted in order to analyze the appropriateness of the par-
allel use of the PCR technique in this group of patients.
However, the most difficult group for clinical assessment
is the intermediate risk group, where PCR, used in parallel
with the intermediary pretest (Clinical Suspicion),
appears not to be useful, as already suggested by others.
The prevalence of PTB may be overestimated in the inter-
mediate risk group, thus the utility of PCR assay in these
patients needs further evaluation, using more accurate
clinical selection criteria [25,30].
The PCR dot-blot was selected due to its low cost (around
U$12), simple extraction method and the colorimetric
end point, all factors that might be expected to facilitate
the transfer of NAA tests to laboratories in low income
countries [28,31]. Additionally, as clinical risk assessment
is more likely to reflect physician decision-making, to our
knowledge, this is the first prospective study that relates
pretest probability with the performance of a PCR in con-
secutive patients suspected of having SNPTB, in South
America.
In our study, we pursued, in a large number of smear neg-
ative pulmonary TB suspects, a comprehensive clinical
and laboratory approach for TB diagnosis using a home-
made PCR, as suggested by Flores et al[32]. Due to the het-
erogeneity in the test's accuracy, it was emphasized the
necessity to incorporate the clinical information for the
better evaluation of NAAs in TB diagnosis among smear
negative cases [32,33].
Another possible study limitation was the use of a home-
made PCR that may warrant validation in comparison
with more reliable techniques, such as an automated
standardized test, as described by Greco et al.[33]. Unfor-
tunately, an automated test was not available, therefore,
the IS6110 element of insertion was used as a target for
PCR; as recent meta-analyses demonstrated its higher
accuracy in the diagnosis of SNPTB [11]. Differing data in
literature may be explained due to some factors. Firstly,
few studies have evaluated the utility of the home-made
PCR technique among SNPTB suspects in developing
nations with a high TB and HIV burden. Secondly, those
studies that measured the clinical risk assessment were
performed in settings with different TB prevalence
[24,25]. Thirdly, clinical judgment and experience can
influence the pretest probabilities, interfering with the
sample size in each clinical risk group. Finally, the preva-
lence of co-morbidities (i.e.: HIV infection) of mycobacte-
ria other than tuberculosis (MOTT) disease and the
patient's response to interview may differ according to
their prevalence in the community.
Conclusion
The PCR dot-blot used in parallel with the high probabil-
ity pretest has a high negative predictive value suggesting
that in a hospital setting in developing countries, with a
high prevalence of TB and HIV, the PCR technique may be
useful for the evaluation of SNPTB suspects. For example,
when the pretest probability is high, a negative PCR result
indicates an increased likelihood of the absence of active
TB in SNPTB suspects, infected or not by HIV.
We conclude that our results are in agreement with those
of the literature, showing that molecular methods may
provide an important contribution to the diagnosis of
SNPTB in patients with high clinical suspicion [24,26].
Since home-made PCR is less costly than automated NAA,
this test could be introduced more widely after a proper
evaluation of its cost-effectiveness with clinical and radio-
graphic characteristics to refine estimates of likelihood of
TB disease in different settings, as proposed by others
[28,34].
Abbreviations
AFB – Acid Fast Bacilli
MOTT – Mycobacterium Other Than Tuberculosis
MTB – Mycobacterium tuberculosis
NAA – Nucleic Acid Amplification
PCR – Polymerase Chain Reaction
PTB – Pulmonary Tuberculosis
SNPTB – Smear Negative Pulmonary Tuberculosis
PRH – Parthenon Reference Hospital
BMC Public Health 2007, 7:356 http://www.biomedcentral.com/1471-2458/7/356
Page 9 of 10
(page number not for citation purposes)
TB – Tuberculosis
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
LCS carried out the study, participated in the laboratory
tests, participated in data acquisition, performed the sta-
tistical analysis and drafted the manuscript; RDS carried
out the laboratory tests, data analysis, participated in data
acquisition and drafted the manuscript, FCQM helped to
draft the manuscript, CJ participated in the recruitment
and in the clinical evaluation of patients, PIC underwent
the questionnaire in patients. SM and MOR performed
bacteriological tests, ARN performed the epidemiological
analysis and drafted the paper, MLRR helped design the
study, performed the statistical analysis and drafted the
paper, ALK conceived of the study, participated in its
design, performed the data analysis, coordination and
helped to draft the manuscript. All authors contributed to
the interpretation of results, have read and approved the
final manuscript.
Acknowledgements
We thank Fabio Mendonça and Candice Tosi Michelon for laboratory sup-
port; CEARGS (Center of studies in AIDS/RS) for statistical support; and 
health personnel from SPRH. Financial Support: This work was supported 
by CNPq, REDETB number 62.005/014PADCT and ICIDR, grant number: 
1 U19 AI45432
References
1. WHO: Global tuberculosis control - surveillance, planning,
financing.  WHO Report 2006 2006:362.
2. Brasil MS: Boletim Eletrônico Epidemiológico do Ministério
da Saúde.  2000.
3. Elliott AM, Namaambo K, Allen BW, Luo N, Hayes RJ, Pobee JO,
McAdam KP: Negative sputum smear results in HIV-positive
patients with pulmonary tuberculosis in Lusaka, Zambia.
Tuber Lung Dis 1993, 74(3):191-194.
4. Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda
H, Wirima JJ, Salaniponi FM, Liomba G, Maher D, Nunn P: Treat-
ment outcome of an unselected cohort of tuberculosis
patients in relation to human immunodeficiency virus
serostatus in Zomba Hospital, Malawi.  Trans R Soc Trop Med
Hyg 1998, 92(3):343-347.
5. Gordin FM, Slutkin G, Schecter G, Goodman PC, Hopewell PC: Pre-
sumptive diagnosis and treatment of pulmonary tuberculo-
sis based on radiographic findings.  Am Rev Respir Dis 1989,
139(5):1090-1093.
6. Dlodlo RA, Fujiwara PI, Enarson DA: Should tuberculosis treat-
ment and control be addressed differently in HIV-infected
and -uninfected individuals?  Eur Respir J 2005, 25(4):751-757.
7. Sloutsky A, Han LL, Werner BG: Practical strategies for per-
formance optimization of the enhanced gen-probe amplified
mycobacterium tuberculosis direct test.  J Clin Microbiol 2004,
42(4):1547-1551.
8. Schijman AG, Losso MH, Montoto M, Saez CB, Smayevsky J,
Benetucci JA: Prospective evaluation of in-house polymerase
chain reaction for diagnosis of mycobacterial diseases in
patients with HIV infection and lung infiltrates.  Int J Tuberc
Lung Dis 2004, 8(1):106-113.
9. Brodie D, Schluger NW: The diagnosis of tuberculosis.  Clin Chest
Med 2005, 26(2):247-71, vi.
10. Perkins MD: New diagnostic tools for tuberculosis.  Int J Tuberc
Lung Dis 2000, 4(12 Suppl 2):S182-8.
11. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller WC:
Assessment by meta-analysis of PCR for diagnosis of smear-
negative pulmonary tuberculosis.  J Clin Microbiol 2003,
41(7):3233-3240.
12. Kivihya-Ndugga L, van Cleeff M, Juma E, Kimwomi J, Githui W, Oskam
L, Schuitema A, van Soolingen D, Nganga L, Kibuga D, Odhiambo J,
Klatser P: Comparison of PCR with the routine procedure for
diagnosis of tuberculosis in a population with high preva-
lences of tuberculosis and human immunodeficiency virus.  J
Clin Microbiol 2004, 42(3):1012-1015.
13. Laifer G, Widmer AF, Frei R, Zimmerli W, Fluckiger U: Polymerase
chain reaction for Mycobacterium tuberculosis: impact on
clinical management of refugees with pulmonary infiltrates.
Chest 2004, 125(3):981-986.
14. Mbulo GM, Kambashi BS, Kinkese J, Tembwe R, Shumba B, Godfrey-
Faussett P, McNerney R: Comparison of two bacteriophage
tests and nucleic acid amplification for the diagnosis of pul-
monary tuberculosis in sub-Saharan Africa.  Int J Tuberc Lung Dis
2004, 8(11):1342-1347.
15. Ribeiro FK, Dettoni Vdo V, Peres RL, Vinhas SA, Co TR, Dietze R,
Palaci M: Evaluation of a commercial test based on ligase
chain reaction for direct detection of Mycobacterium tuber-
culosis in respiratory specimens.  Rev Soc Bras Med Trop 2004,
37(6):431-435.
16. Sperhacke RD, Mello FC, Zaha A, Kritski A, Rossetti ML: Detection
of Mycobacterium tuberculosis by a polymerase chain reac-
tion colorimetric dot-blot assay.  Int J Tuberc Lung Dis 2004,
8(3):312-317.
17. Tarhan G, Saygan MB, Cesur S, Ocak F, Ceyhan I: [Retrospective
evaluation of Cobas Amplicor system in the rapid diagnosis
of Mycobacterium tuberculosis complex].  Mikrobiyol Bul 2005,
39(1):35-41.
18. Tuberculose IICB: Diretrizes Brasileiras para Tuberculose.  Jor-
nal Brasileiro de Pneumologia 2004, 30(1):.
19. Mello FC, Bastos LG, Soares SL, Rezende VM, Conde MB, Chaisson
RE, Kritski AL, Ruffino-Netto A, Werneck GL: Predicting smear
negative pulmonary tuberculosis with classification trees
and logistic regression: a cross-sectional study.  BMC Public
Health 2006, 6:43.
20. ATS: Diagnostic Standards and Classification of Tuberculosis
in Adults and Children. This official statement of the Amer-
ican Thoracic Society and the Centers for Disease Control
and Prevention was adopted by the ATS Board of Directors,
July 1999. This statement was endorsed by the Council of the
Infectious Disease Society of America, September 1999.  Am
J Respir Crit Care Med 2000, 161(4 Pt 1):1376-1395.
21. Kent PT KG: Public Health Mycobacteriology – a guide for
level III laboratory.  Centers for Disease Control and Prevention 1985.
22. Medronho RA, CDM, Bloch KV, Luiz RR, Werneck GL: Epidemio-
logia.  Editora Atheneu, Sao Paulo 2002.
23. Secretaria Municipal de Porto Alegre. Coordenadoria de Vigilancia
em Saude. Equipe de Controle Epidemiologico: Análise compara-
tiva do ingresso de casos novos de Tuberculose ocorrido na
rede ambulatorial e hospitalar de Porto Alegre nos anos de
2003 e 2004.  Boletim Epidemiológico 2005, 27(Ano VIII):.
24. Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S,
LoBue PA, Peter C, Pfyffer GE, Sierra MF, Weber R, Woods G, Math-
ews G, Jonas V, Smith K, Della-Latta P: The role of clinical suspi-
cion in evaluating a new diagnostic test for active
tuberculosis: results of a multicenter prospective trial.  Jama
2000, 283(5):639-645.
25. Lim TK, Gough A, Chin NK, Kumarasinghe G: Relationship
between estimated pretest probability and accuracy of auto-
mated Mycobacterium tuberculosis assay in smear-negative
pulmonary tuberculosis.  Chest 2000, 118(3):641-647.
26. Piersimoni C, Nista D, Zallocco D, Galassi M, Cimarelli ME, Tubaldi
A: Clinical suspicion as a primary guidance to use commer-
cial amplification tests for rapid diagnosis of pulmonary
tuberculosis.  Diagn Microbiol Infect Dis 2005, 53(3):195-200.
27. Goessens WH, de Man P, Koeleman JG, Luijendijk A, te Witt R, Endtz
HP, van Belkum A: Comparison of the COBAS AMPLICOR
MTB and BDProbeTec ET assays for detection of Mycobac-
terium tuberculosis in respiratory specimens.  J Clin Microbiol
2005, 43(6):2563-2566.
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Public Health 2007, 7:356 http://www.biomedcentral.com/1471-2458/7/356
Page 10 of 10
(page number not for citation purposes)
28. van Cleeff M, Kivihya-Ndugga L, Githui W, Ng'ang'a L, Kibuga D,
Odhiambo J, Klatser P: Cost-effectiveness of polymerase chain
reaction versus Ziehl-Neelsen smear microscopy for diagno-
sis of tuberculosis in Kenya.  Int J Tuberc Lung Dis 2005,
9(8):877-883.
29. Almeda J, Garcia A, Gonzalez J, Quinto L, Ventura PJ, Vidal R, Rufi G,
Martinez JA, Jimenez de Anta MT, Trilla A, Alonso PL: Clinical eval-
uation of an in-house IS6110 polymerase chain reaction for
diagnosis of tuberculosis.  Eur J Clin Microbiol Infect Dis 2000,
19(11):859-867.
30. Lim TK, Mukhopadhyay A, Gough A, Khoo KL, Khoo SM, Lee KH,
Kumarasinghe G: Role of clinical judgment in the application of
a nucleic acid amplification test for the rapid diagnosis of pul-
monary tuberculosis.  Chest 2003, 124(3):902-908.
31. Dowdy DW, Maters A, Parrish N, Beyrer C, Dorman SE: Cost-
effectiveness analysis of the gen-probe amplified mycobacte-
rium tuberculosis direct test as used routinely on smear-pos-
itive respiratory specimens.  J Clin Microbiol 2003, 41(3):948-953.
32. Flores LL, Pai M, Colford JM Jr., Riley LW: In-house nucleic acid
amplification tests for the detection of Mycobacterium
tuberculosis in sputum specimens: meta-analysis and meta-
regression.  BMC Microbiol 2005, 5:55.
33. Greco S, Girardi E, Navarra A, Saltini C: Current evidence on
diagnostic accuracy of commercially based nucleic acid
amplification tests for the diagnosis of pulmonary tuberculo-
sis.  Thorax 2006, 61(9):783-790.
34. Lim TK, Cherian J, Poh KL, Leong TY: The rapid diagnosis of
smear-negative pulmonary tuberculosis: a cost-effectiveness
analysis.  Respirology 2000, 5(4):403-409.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/7/356/pre
pub
